Validant acquires DataRevive, a regulatory strategy and consulting business focused on novel therapeutics and biologics

Posted: 1 Nov 2019

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of DataRevive.

Validant, a leading transatlantic quality, compliance and regulatory consulting group, has acquired DataRevive, a regulatory strategy and consultancy firm that focuses on supporting pharma and biotech to navigate the regulatory approval pathway for global clients in the US market.

Validant’s acquisition of DataRevive is part of its international growth strategy through both organic expansion and selective acquisitions and follows its partnership with GHO Capital, a leading specialist healthcare investment adviser based in London, in December 2018.

The combination of DataRevive and Validant will strengthen and expand the combined group’s service offering across regulatory driven life science consulting and allow both businesses to better serve their clients across the development lifecycle.

Established in 2016 by Audrey Jia, CEO, DataRevive is constructed around a high-quality partner base, with a mixture of ex-FDA and industry employees that bring unique expertise into the business. DataRevive focuses on novel therapeutics and biologics, the fastest growth segments of the market.

The acquisition adds a new location in Washington D.C. to complement Validant’s existing footprint in San Francisco, the Research Triangle Park in North Carolina and Cork, Ireland. With many international clients, DataRevive also broadens the group’s exposure to and expertise in significant new growth markets.

Commenting on the announcement, Brian Burns, CEO of Validant said: “We’re delighted to announce our acquisition of DataRevive and are excited about the combination with Validant. The DataRevive team brings a wealth of knowledge and new expertise into the business, complementing the Validant team. Together, we are in a better position to support our existing and new clients manage their regulatory and quality needs.

Joining forces with Validant will provide new commercial channels to deliver our services to a broader array of global biopharma customers. It will also strengthen our capability to provide world class quality and compliance services to enable our clients to achieve and maintain marketing applications globally” said Audrey Jia, CEO of DataRevive. “Our team are looking forward to being able to leverage the Validant network and best-in-class operating model to support a broader and growing customer base.”

Further information:

Charles Cox
Investor Relations Director
T +44 20 3700 7440
E [email protected]

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare. For further information, please visit

About Validant
Validant is a leading international Quality, Compliance, and Regulatory consulting firm, blending industry expertise with innovation to create custom solutions for companies on the frontier of health. The Validant network represents the largest assembly of leading engineers, scientists, clinicians, and specialists in the field. With deep experience working within and alongside the FDA, health authority, and other regulatory agencies, we understand how to navigate the complexities facing today’s healthcare industry. For further information, please visit

About DataRevive
DataRevive is a leading Regulatory Affairs consulting firm, providing high quality advice and expertise from the perspective of industry and regulators to support customers from across pharma and biotech as they seek to navigate the regulatory approval process. For further information, please visit